Meeting
2012 ASCO Annual Meeting
Effect of oxaliplatin-based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: A pooled analysis of individual patient data from four randomized controlled trials.
Authors
Christopher Twelves
University of Leeds and St. James's University Hospital, Leeds, United Kingdom
Christopher Twelves , Hans-Joachim Schmoll , Michael O'Connell , Thomas H. Cartwright , Edward McKenna , Weijing Sun , Wasif M. Saif , Luen F. Lee , Greg Yothers , Daniel G. Haller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3523)
DOI
10.1200/jco.2012.30.15_suppl.3523
Abstract #
3523
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.
First Author: Daniel G. Haller
Poster
2011 Gastrointestinal Cancers Symposium
Review of completed and ongoing trials of capecitabine-based adjuvant therapy in patients with early-stage colon cancer.
First Author: James Cassidy
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.
First Author: Daniel Walden
Poster
2020 ASCO Virtual Scientific Program
POF (paclitaxel/oxaliplatin/5-FU/leucovorin) versus SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial.
First Author: Liyu Su